Login
Home
Charts
Search
Watchlist
Products

Mankind Pharma Ltd

MANKIND·NSE
₹2,500.00+1.42%Thu, 24 Sept '26
Industry:Pharma - Formulators
Indices:

Mankind Pharma Ltd

MANKIND
NSE
₹2,500.00
+1.42%
|Thu, 24 Sept '26
SOICxStockScans Reports
Industry
Pharma - Formulators
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹1,03,261Cr
Close
Close Price
₹2,500.00
Industry
Industry
Pharma - Formulators
PE
Price To Earnings
50.52
PS
Price To Sales
7.01
Revenue
Revenue
₹14,738Cr
Rev Gr TTM
Revenue Growth TTM
14.16%
PAT Gr TTM
PAT Growth TTM
8.10%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
2,7082,6072,4222,8683,0613,1993,0793,5703,6973,5673,4434,031
Growth YoY
Revenue Growth YoY%
11.624.718.011.213.122.727.124.520.811.511.812.9
Expenses
ExpensesCr
2,0252,0001,8362,1962,2142,3832,3962,7242,7762,6482,5132,974
Operating Profit
Operating ProfitCr
6836075866728478166838479219199301,056
OPM
OPM%
25.223.324.223.427.725.522.223.724.925.827.026.2
Other Income
Other IncomeCr
637595103112802548394-319449
Interest Expense
Interest ExpenseCr
999117221191171170157142110
Depreciation
DepreciationCr
96110100103100187231219222223223226
PBT
PBTCr
641562572661851488515540624509659769
Tax
TaxCr
13010395123190110869610495100195
PAT
PATCr
511460477543659385425445520414559574
Growth YoY
PAT Growth YoY%
20.955.562.39.928.9-16.4-10.9-18.1-21.17.631.729.1
NPM
NPM%
18.917.619.718.921.512.013.812.414.111.616.314.2
EPS
EPS₹
12.511.311.813.416.39.510.210.612.49.913.413.8
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
2,7082,6072,4222,8683,0613,1993,0793,5703,6973,5673,4434,031
Growth YoY
Revenue Growth YoY%
11.624.718.011.213.122.727.124.520.811.511.812.9
Expenses
ExpensesCr
2,0252,0001,8362,1962,2142,3832,3962,7242,7762,6482,5132,974
Operating Profit
Operating ProfitCr
6836075866728478166838479219199301,056
OPM
OPM%
25.223.324.223.427.725.522.223.724.925.827.026.2
Other Income
Other IncomeCr
637595103112802548394-319449
Interest Expense
Interest ExpenseCr
999117221191171170157142110
Depreciation
DepreciationCr
96110100103100187231219222223223226
PBT
PBTCr
641562572661851488515540624509659769
Tax
TaxCr
13010395123190110869610495100195
PAT
PATCr
511460477543659385425445520414559574
Growth YoY
PAT Growth YoY%
20.955.562.39.928.9-16.4-10.9-18.1-21.17.631.729.1
NPM
NPM%
18.917.619.718.921.512.013.812.414.111.616.314.2
EPS
EPS₹
12.511.311.813.416.39.510.210.612.49.913.413.8

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5,8656,2147,7828,74910,26012,20714,27814,738
Growth
Revenue Growth%
6.025.212.417.319.017.014.2
Expenses
ExpensesCr
4,4284,5665,7926,8497,7479,19010,66010,911
Operating Profit
Operating ProfitCr
1,4371,6481,9891,9012,5143,0183,6173,827
OPM
OPM%
24.526.525.621.724.524.725.326.0
Other Income
Other IncomeCr
122183210141295549241207
Interest Expense
Interest ExpenseCr
2220594433429639579
Depreciation
DepreciationCr
99119167326378621886893
PBT
PBTCr
1,4381,6921,9751,6712,3982,5162,3332,562
Tax
TaxCr
382399522362457510395494
PAT
PATCr
1,0561,2931,4531,3101,9412,0071,9382,068
Growth
PAT Growth%
22.412.4-9.948.23.4-3.48.1
NPM
NPM%
18.020.818.715.018.916.413.614.0
EPS
EPS₹
25.731.635.832.047.849.346.449.5
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5,8656,2147,7828,74910,26012,20714,27814,738
Growth
Revenue Growth%
6.025.212.417.319.017.014.2
Expenses
ExpensesCr
4,4284,5665,7926,8497,7479,19010,66010,911
Operating Profit
Operating ProfitCr
1,4371,6481,9891,9012,5143,0183,6173,827
OPM
OPM%
24.526.525.621.724.524.725.326.0
Other Income
Other IncomeCr
122183210141295549241207
Interest Expense
Interest ExpenseCr
2220594433429639579
Depreciation
DepreciationCr
99119167326378621886893
PBT
PBTCr
1,4381,6921,9751,6712,3982,5162,3332,562
Tax
TaxCr
382399522362457510395494
PAT
PATCr
1,0561,2931,4531,3101,9412,0071,9382,068
Growth
PAT Growth%
22.412.4-9.948.23.4-3.48.1
NPM
NPM%
18.020.818.715.018.916.413.614.0
EPS
EPS₹
25.731.635.832.047.849.346.449.5

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
40404040404141
Reserves
ReservesCr
3,4454,6826,1157,3959,32314,29116,259
Current Liabilities
Current LiabilitiesCr
1,2591,3532,6231,8632,1205,6646,507
Non Current Liabilities
Non Current LiabilitiesCr
1431562082292687,5285,011
Total Liabilities
Total LiabilitiesCr
5,0736,3739,1489,71511,96327,76028,080
Current Assets
Current AssetsCr
2,8223,9074,4074,3286,5686,9886,954
Non Current Assets
Non Current AssetsCr
2,2512,4664,7415,3885,39520,77121,125
Total Assets
Total AssetsCr
5,0736,3739,1489,71511,96327,76028,080
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
40404040404141
Reserves
ReservesCr
3,4454,6826,1157,3959,32314,29116,259
Current Liabilities
Current LiabilitiesCr
1,2591,3532,6231,8632,1205,6646,507
Non Current Liabilities
Non Current LiabilitiesCr
1431562082292687,5285,011
Total Liabilities
Total LiabilitiesCr
5,0736,3739,1489,71511,96327,76028,080
Current Assets
Current AssetsCr
2,8223,9074,4074,3286,5686,9886,954
Non Current Assets
Non Current AssetsCr
2,2512,4664,7415,3885,39520,77121,125
Total Assets
Total AssetsCr
5,0736,3739,1489,71511,96327,76028,080

Cash Flow

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1,0701,1379201,8132,1522,4133,121
Investing Cash Flow
Investing Cash FlowCr
-439-1,222-1,369-1,054-2,082-12,683-196
Financing Cash Flow
Financing Cash FlowCr
-531-8605-740510,233-2,953
Net Cash Flow
Net Cash FlowCr
100-931551976-37-28
Free Cash Flow
Free Cash FlowCr
8788334581,0301,8451,9652,498
CFO To PAT
CFO To PAT%
101.388.063.3138.4110.9120.3161.1
CFO To EBITDA
CFO To EBITDA%
74.569.046.295.485.680.086.3
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
1,0701,1379201,8132,1522,4133,121
Investing Cash Flow
Investing Cash FlowCr
-439-1,222-1,369-1,054-2,082-12,683-196
Financing Cash Flow
Financing Cash FlowCr
-531-8605-740510,233-2,953
Net Cash Flow
Net Cash FlowCr
100-931551976-37-28
Free Cash Flow
Free Cash FlowCr
8788334581,0301,8451,9652,498
CFO To PAT
CFO To PAT%
101.388.063.3138.4110.9120.3161.1
CFO To EBITDA
CFO To EBITDA%
74.569.046.295.485.680.086.3

Ratios

Consolidated
Standalone
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
92,02999,97482,8071,03,261
Price To Earnings
Price To Earnings
48.150.21.150.5
Price To Sales
Price To Sales
9.08.25.87.0
Price To Book
Price To Book
9.87.00.16.3
EV To EBITDA
EV To EBITDA
36.435.824.528.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
65.168.566.163.966.068.168.268.2
OPM
OPM%
24.526.525.621.724.524.725.326.0
NPM
NPM%
18.020.818.715.018.916.413.614.0
ROCE
ROCE%
40.434.528.922.625.412.913.113.1
ROE
ROE%
30.327.423.617.620.714.011.911.9
ROA
ROA%
20.820.315.913.516.27.26.96.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
92,02999,97482,8071,03,261
Price To Earnings
Price To Earnings
48.150.21.150.5
Price To Sales
Price To Sales
9.08.25.87.0
Price To Book
Price To Book
9.87.00.16.3
EV To EBITDA
EV To EBITDA
36.435.824.528.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
65.168.566.163.966.068.168.268.2
OPM
OPM%
24.526.525.621.724.524.725.326.0
NPM
NPM%
18.020.818.715.018.916.413.614.0
ROCE
ROCE%
40.434.528.922.625.412.913.113.1
ROE
ROE%
30.327.423.617.620.714.011.911.9
ROA
ROA%
20.820.315.913.516.27.26.96.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Mankind Pharma Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/9yotygu210ev7hf4y0yaukry.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/xpqi29tihyj562ht0hpgqom5.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/bb9aa87vzqqgne6bwkkldtui.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/71bj7zuv8nsuvwk99gi7i5ni.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/8gxifj3sb9yuovfbkjefu2wv.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/jbksdq9mw9xjpnakbnmxfy7o.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/2nrsq1jbe6eh00wjd0xl2t99.pdf
  • Q1 FY2025 Earnings Call Transcript (Jun 2024, PDF): https://www.stockscans.in/document/39541y3z1u4frnb8ohmx0ru9.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/yrypm0s0il6b93qlb8sowaa5.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/v87ge29wya322lgjuzyykjy1.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/ljkw7dftdkj2iz505dv3x3mu.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/3tn5n1wh4yywjq095b4ai37k.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/bqpu4xfmb5r6p8utyn9blcj0.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/mit4fejm5z654optay6s4ja1.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/lx0l22a0qaviwler894ld7wq.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/zwbz1uvo4cl41h19lqfmnbd9.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/vcfudrl51tyls7if3tydu4e1.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/7n8wa849wm6624yua0naow8f.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/i3tpekemgah1tiuwipd9whmu.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/0bk546s4n49y9cchrrlpgzya.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/a1zd5i2x6se4bs9ap2rwkqpd.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/us5w2g38bzlutywdqt3aqgbn.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/i3vosy8rdqfdc0twk65lwoxq.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/nlj31uro0lv622jfch5ublzv.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/6ht60ec43ty1q5e6s68913fu.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/ekhde77xr1rdb498yjoi2m2z.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/9xigftvt11npj0yxu229eouu.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/7k4kfkixhlyswimiwb3bt9rz.pdf

Concall Transcript Summaries — Mankind Pharma Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202606/9yotygu210ev7hf4y0yaukry.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202603/xpqi29tihyj562ht0hpgqom5.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202512/bb9aa87vzqqgne6bwkkldtui.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202509/71bj7zuv8nsuvwk99gi7i5ni.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202503/8gxifj3sb9yuovfbkjefu2wv.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202412/jbksdq9mw9xjpnakbnmxfy7o.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202409/2nrsq1jbe6eh00wjd0xl2t99.pdf
  • Q1 FY2025 Concall Transcript Summary (Jun 2024): https://www.stockscans.in/company/NSE%3AMANKIND/transcript-notes/202406/39541y3z1u4frnb8ohmx0ru9.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies